<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382339</url>
  </required_header>
  <id_info>
    <org_study_id>SOF-PEG</org_study_id>
    <nct_id>NCT04382339</nct_id>
  </id_info>
  <brief_title>Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4</brief_title>
  <acronym>HCV</acronym>
  <official_title>Effectiveness of Sofosbuvir/Pegylated-interferon Plus Ribavirin in Treatment of Hepatitis C Virus Genotype 4 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated
      interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between March 2015 and November 2015, 99 participants (59 naïve and 40 experienced) infected
      with HCV GT4 were enrolled in the study. Eligible participants received daily oral 400 mg SOF
      ( (Sovaldi, Gilead Sciences, Inc., USA), RBV (Copegus, Roche, Europe) based on body weight: &lt;
      75 kg, 1000 mg; ≥75 kg, 1200 mg), the dose modified according to participants tolerability,
      plus 180 μg PegINFα-2 once weekly for 12 weeks.

      Experienced participants included participants with a prior relapse or a null response to
      PegINF/RBV therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm SVR12</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <description>SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) &lt; 15 IU/m 12 weeks after the last dose of drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events in Each Treatment Arm</measure>
    <time_frame>Screening until 30 days after last dose</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant or i clinical investigation after administering a pharmaceutical drugs serious adverse event (SAE) is an event that results in death, life-threatening, requires hospitalization, or significant disability/incapacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral relapse</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <description>Viral relapse was HCV RNA undetectable at EOT, but detectable HCV RNA &gt; 15 IU/ml levels 12 weeks after planned EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Virologic Failure</measure>
    <time_frame>up tp 24 weeks</time_frame>
    <description>On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with HCV RNA greater than 15 IU/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Treatment-naive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-experienced</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/RBV/PegINFα-2</intervention_name>
    <description>SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C</description>
    <arm_group_label>Treatment-experienced</arm_group_label>
    <arm_group_label>Treatment-naive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The study population consisted of treatment-naïve and treatment-experienced adults patients
        aged 20-65 with HCV RNA level &gt; 10,000 IU/ml.

        Experienced participants included those with a prior relapse or a null response to
        PegINF/RBV therapy.

        -

        Exclusion Criteria:Participants with one or more of

          -  HCV coinfected with hepatitis B virus (HBV)

          -  human immunodeficiency virus (HIV)

          -  had any liver disease other than chronic HCV GT4 infection.

          -  had a history of liver decompensation

          -  serum a-fetoprotein (AFP) &gt; 100 ng/ml

          -  evidence of hepatocellular carcinoma

          -  major severe illness such as respiratory, renal, heart failure or autoimmune disease

          -  non-compliance with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Abdel-Gabbar, Ass. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621</affiliation>
  </overall_official>
  <link>
    <url>https://www.termedia.pl/Effectiveness-of-sofosbuvir-pegylated-interferon-plus-ribavirin-in-treatment-of-hepatitis-C-virus-genotype-4-patients,80,33652,0,1.html</url>
    <description>The link clarify the effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients</description>
  </link>
  <results_reference>
    <citation>Abdel-Moneim A, Abood A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients. Clin Exp Hepatol. 2018 Sep;4(3):191-196. doi: 10.5114/ceh.2018.78123. Epub 2018 Sep 10.</citation>
    <PMID>30324144</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mohammed Abdel-Gabbar, Ph.D</investigator_full_name>
    <investigator_title>Associate Prof</investigator_title>
  </responsible_party>
  <keyword>HCV genotype 4</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>Peg-interferon α-2</keyword>
  <keyword>ribavirin</keyword>
  <keyword>Egyptian patients</keyword>
  <keyword>Experinced</keyword>
  <keyword>Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

